13
Jan
Warning to Be Removed from GLP-1 Labeling - Lachman Blog

Warning to Be Removed from GLP-1 Labeling

Typically, when the FDA issues a labeling safety warning, it means that a new warning is being added to existing labeling. However, in an FDA safety notice published today titled FDA Requests Removal of Suicidal Behavior and Ideation [SI/B] Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications (here), the FDA is advising GLP-1 RA […]

Read More
13
Jan
Voucher - Lachman Blog

Seems That I’m Not the Only One Who’s Worried!

I’ve been blogging about FDA Commissioner Markay’s National Priority Voucher program since it was announced in June 2025 (here, here, here, here, and here). In these blogs, I’ve raised the following concerns: The compressed one- to two-month timeframe creates a potential opportunity for missing something important during these reviews. With the competition for resources for […]

Read More
06
Jan
Group of medical bottles with liquid and vaccine bottle in doctor's office, stock photo

FDA Posts ICH Q3E Guideline on Extractables and Leachables: Comment Period Still Open

The International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) endorsed a new draft guidance on extractables and leachables in August 2025 that the FDA has since published for review and comment.  The version published by the FDA is accessible at Q3E Guideline for Extractables and Leachables and includes Supporting Documentation: […]

Read More
23
Dec
FSD gage

Does Your Data Integrity Risk Assessment Assess Full-Scale Instrument Deflection? It Should!

Why Using Full-Scale Deflection Introduces Data Integrity Risks In pharmaceutical manufacturing, Accuracy is a critical ALCOA+ principle that can sometimes get lost, particularly when assessing the holistic system. The field instrument level needs to be adequately integrated into the overall assessment, especially in aseptic manufacturing environments where sterilization is critical (and accurate data, such as […]

Read More
15
Dec
Safety Reporting Requirements - Lachman Blog

FDA Issues Two Guidance Documents to Help Sponsors with Safety Reporting Requirements

In an email announcing the two new guidances, the FDA said, “[t]he first guidance titled Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices is intended for investigators, industry, and institutional review boards (IRBs). This final guidance provides recommendations to help clinical investigators comply with the safety reporting requirements for investigational new drug application […]

Read More
26
Nov
Rise of Bio-Incubator Spaces - Lachman Blog

The Rise of Bio-Incubator Spaces: Redefining Asset Development in Life Sciences

The life-sciences industry has long been synonymous with high barriers to entry. Traditional research and development (R&D) models demand enormous capital investment, specialized infrastructure, and a deep understanding of regulatory compliance. For startups and innovators, these requirements often translate into years of fundraising and risk before a single product reaches the market. However, the emergence […]

Read More
25
Nov
Nitrosamine Issue Resolved for Ranitidine - Lachman Blog

Nitrosamine Issue Resolved for Ranitidine – New Formulation Approved

On November 24, 2025, the FDA announced (here) that, following a comprehensive safety review, it has approved a reformulated ranitidine tablet, “marking the return of this important acid-reducing medication to the U.S. market after a five-year absence. The approval follows extensive safety testing and manufacturing improvements that address previous concerns about N-nitrosodimethylamine (NDMA) impurity formation during […]

Read More
24
Nov
Debarments Continue - Lachman Blog

Debarments Continue – How Many and for What?

The process of debarment began after the generic drug scandal in the late 1980s and the FDA continues to use this process to preclude individuals from participating in a variety of activities, including drug development, manufacture, clinical studies in support of drug applications, and importing drugs into this country if they are have been convicted […]

Read More
1 … 4 5 6 … 35